Table 3.
Selected additional analyses undertaken by the company and the ERG (using the new PAS)
| Technology | Incremental costs (£) | Incremental QALYs | ICER, £/QALY gained |
|---|---|---|---|
| Company base case | 16,055 | 0.56 | 28,563 |
| Company base case + piecewise curve | 15,855 | 0.48 | 32,849 |
| ERG base casea | 15,089 | 0.43 | 35,486 |
| ERG base caseb | 16,098 | 0.43 | 37,859 |
| ERG base casec | 16,184 | 0.43 | 38,061 |
| ERG base case + piecewise curve | 15,938 | 0.31 | 51,026 |
| ERG base case + piecewise curve (without arbitrarily limiting TTD to a maximum of 1000 days for BSC only) | 15,908 | 0.29 | 54,091 |
PAS patient access scheme, QALY quality-adjusted life-year, ICER incremental cost-effectiveness ratio, ERG Evidence Review Group, TTD time to treatment discontinuation, BSC best supportive care, AA abiraterone acetate, AAP AA in combination with prednisone/prednisolone
aERG base case, including the new PAS for both BSC (post-docetaxel AA) and AAP (pre-docetaxel AA), not including the PAS administration fee (for the new PAS)
bERG base case, including the old PAS for BSC (post-docetaxel AA) and the new PAS for AA (pre-docetaxel AA), not including the PAS administration fee (for the new PAS)
cERG base case, including the old PAS for BSC (post-docetaxel AA) and the new PAS for AA (pre-docetaxel AA), including the PAS administration fee (for the new PAS)